Sanofi to acquire Kymab, adding a human monoclonal antibody KY1005 to
its pipeline Sanofi will be acquiring Kymab, a clinical-stage
biopharmaceutical company that works on immuno-oncology therapeutics
and immune-mediated diseases, developing completely human monoclonal
antibodies. The agreement involves a 1.1 billion dollars upfront
payment and 350 million dollars upon attaining some milestones. Kymab
has developed […]
The post Sanofi To Acquire Kymab, Adding A Human Monoclonal Antibody
KY1005 To Its Pipeline appeared first on Rasayanika .
https://www.rasayanika.com/2021/01/14/sanofi-to-acquire-kymab-adding-a-human-monoclonal-antibody-ky1005-to-its-pipeline/
News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment